The company said it took financial hits from the Inflation Reduction Act's Medicare Part D redesign, which included higher ...

Pfizer Inc. (NYSE: PFE) will showcase data across its portfolio of potential breakthrough cancer medicines at the 2025 ...

Pfizer (NYSE:PFE) reported positive topline results from a Phase 3 study of its drug Braftovi, also known as encorafenib, in the treatment of a certain type of colorectal cancer. The study ...

Pfizer Inc.'s stock is trading at $22 with an 8% dividend yield, driven by market fears over losing vaccine revenues. Read ...

BEACON CRC also included another three drug arm – Braftovi, Erbitux, and MEK inhibitor Mektovi (binimetinib) from Array Biopharma (now part of Pfizer). That wasn’t able to improve survival any ...

Pfizer (PFE) will showcase data across its portfolio of potential breakthrough cancer medicines at the 2025 American ...

As tough as it may be to do right now, this is a great time to hold your nose and dive in while yields are as high as they ...

Sales of Xtandi, Lorbrena and Braftovi/Mektovi are likely to have increased. The antibody-drug conjugates or ADCs — Adcetris, Padcev, Tukysa and Tivdak — added to Pfizer’s portfolio with the ...

highlight advancements across Pfizer’s industry-leading Oncology portfolio ASCO press program to feature overall survival and progression-free survival data for BRAFTOVI® (encorafenib ...

Pfizer Oncology. “Important early-stage updates highlight our extensive pipeline and depth within our core cancer types, as we advance up to nine new pivotal phase 3 trials this year.” Key ASCO ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) will showcase data across its portfolio of potential breakthrough cancer medicines at the 2025 American Society of Clinical Oncology (ASCO ...